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Background: The oral prednisolone test is widely used to distinguish chronic obstructive 
pulmonary disease (COPD) patients who might benefit from inhaled steroid treatment. Previous 
studies used selected patient groups that did not represent the large COPD population in 
primary care.
Methods: The study included smokers and exsmokers with chronic bronchitis or COPD from 
primary care, who underwent prednisolone testing (30 mg for 14 days) before randomization in 
a three-year follow-up randomized controlled trial (COOPT Study). Spirometry was performed 
before and after the test. Responders and nonresponders were classified according to international 
criteria. Effectiveness of inhaled fluticasone relative to placebo was compared in terms of health 
status (Chronic Respiratory Disease Questionnaire), exacerbations, and postbronchodilator 
forced expiratory volume in one second (FEV
1
), using repeated measurement analysis.
Results: Two hundred eighty-six patients recruited from 44 primary care practices were 
randomized. Nine percent to 16% of the COPD population was classified as responder, depending 
on the international guideline criteria used. On average, responders did not reach the minimum 
clinically important difference in health status (0.29 points/year, P = 0.05), although a borderline 
significant effect of inhaled fluticasone was noted. Possible clinically relevant reductions in 
exacerbation rate (rate ratio 0.67) and FEV
1
 decline (39 mL/year) occurred in responders, but 
did not reach statistical significance.
Conclusions: Oral steroid testing identifies a limited proportion of COPD patients, but does 
not reveal any clinically relevant benefit from inhaled steroid treatment on health status. No 
significant effects on exacerbation rate and lung function decline occurred.
Keywords: COPD, primary care, oral steroid testing, prednisolone test
Background
In chronic obstructive pulmonary disease (COPD), many different patient groups are 
represented. Patients include those with chronic bronchitis to the emphysematous, with 
overweight or with nutritional depletion, and from irreversible obstruction to having 
a reversible component besides persistent obstruction. By GOLD definition,1 and in 
daily practice, all these groups are termed COPD. In most recent (therapeutic) COPD 
trials,2,3 however, a strong entry selection occurred to ensure population homogeneity, 
thereby diminishing external validity.4 From large prospective studies2,3,5,6 it has become 
clear that the progressive lung function loss in COPD cannot be altered by inhaled 
corticosteroid therapy. However, these randomized clinical trials strictly excluded 
patients with any form of reversibility for methodological reasons.7 In practice, the 
diagnostic prednisolone test has been used widely to identify the patients responding 
International Journal of COPD 2009:4432
Chavannes et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
to oral steroids, thus foreshadowing the presumable efficacy 
of inhaled corticosteroid therapy. It is disputed what propor-
tion of COPD patients suffer from persistent obstruction with 
a reversible component. Estimates differ from 10% to 30% 
depending on clinical setting.7–9 It is estimated that 20%–30% 
of patients with COPD may experience a significant improve-
ment in FEV
1
 from short-term corticosteroid use.7,10–12
In case of persistent obstruction with a significant 
reversible component, a diagnostic prednisolone test can be 
performed, although the validity of this test is questioned and 
different cut-off points for ‘response’ are advised according 
to several international guidelines.1,13–15 As a consequence, the 
utility and predictive value of responders within the COPD 
population is vigorously debated.7,9 Small, short-term studies 
in selected patient groups have described different regimes of 
prednisolone testing, and as a result the more or less accepted 
current form (14 days of 30 mg prednisolone) has been part 
of the diagnostic work-up of COPD-patients.16–19 However, 
the prednisolone test was never validated prospectively 
in a primary care population.20 In severe disease without 
reversibility it has recently been shown not to be useful by 
American Thoracic Society (ATS) criteria.21 As a result, it 
was concluded that a short course of oral corticosteroids is 
a poor predictor of the long-term response to inhaled cor-
ticosteroids in COPD. The aim of this study was therefore 
to determine the predictive value and usefulness of the 
prednisolone test; to what extent is the clinical efficacy of 
inhaled corticosteroids (fluticasone propionate 500 µg bid) 
versus placebo related to a positive test response in a primary 
care population during three years of follow-up.
Methods
The COOPT trial22 is a double-blind, double-dummy, 
randomized placebo-controlled clinical trial with a 
three-year follow-up undertaken in The Netherlands between 
1998 and 2004. General practitioner (GP)-diagnosed patients 
with chronic bronchitis and COPD from 44 general practices 
participated in the study, when postbronchodilator forced 
expiratory volume in one second (FEV
1
) was between 
40%–90% predicted, and FEV
1
/forced vital capacity (FVC) 
was below 88% (males) or 89% (females) according to for-
mer European Respiratory Society (ERS) criteria.13 A clear 
history of asthma, allergic rhinitis, or atopic eczema was an 
exclusion criterion, while reversibility to bronchodilators 
was not. Outcome measures were health status, as measured 
with the Chronic Respiratory Disease Questionnaire (CRQ),23 
exacerbation frequency and postbronchodilator FEV
1
. An 
exacerbation was defined as an episode with one or more 
subsequent unscheduled contacts with either a GP or a 
pulmonologist due to worsening of respiratory symptoms. 
In this randomized clinical trial a three-leg design was used, 
with fluticasone propionate and N-acetylcysteine as inter-
vention groups, the third leg as placebo. An independent 
statistician generated a randomization list based on a block 
size of three for treatment allocation to balance the three 
treatment arms by study center. Neither investigators nor 
patients were aware of the group assignment. In this analysis 
we compared the fluticasone propionate 500 ug twice daily 
administered as dry powder inhalation by Diskus inhaler 
versus placebo legs. A wash-out period of three months 
preceded the study, allowing any effects of stopping inhaled 
steroids or N-acetylcysteine to subside. During this wash-out 
phase, 12% of original study candidates withdrew. In effect, 
the study group can be described as patients clinically 
diagnosed as having COPD by their GP, but who did not 
get worse if inhaled steroids were stopped for three months. 
Before randomization took place, all patients underwent 
the prednisolone test, before and after which lung function 
measurements were taken. The study was approved by the 
medical ethics review boards of the hospitals involved. All 
study subjects gave written informed consent.
The diagnostic prednisolone test is generally defined 
as FEV
1
 measurements before and after 14 days of 30 mg 
prednisolone, but cut-off points for a positive response 
differ among the various international guidelines. The ATS14 
considered an increase of 12% and 200 mL of baseline 
FEV
1
 as a positive response, while the British Thoracic 
Society (BTS)15 stated an increase of 15% of baseline 
FEV
1
 as a positive response. By contrast, the ERS13 used 
to recommend a 10% increase of FEV
1
 predicted in their 
guidelines, but this recommendation has been left out in 
the 2004 ERS/ATS Guidelines.24 Specific criteria for posi-
tive response have consequently also been deleted from the 
British NICE Guidelines25 and the executive summary of the 
GOLD Guidelines.1
Differences in longitudinal scores on health status, 
exacerbation frequency, and postbronchodilator FEV
1
 were 
tested on an intention to treat basis, by using statistical 
techniques for repeated measurements. The placebo group 
has been taken as representing the natural course, relative to 
the intervention groups. For statistical testing of differences 
in exacerbation frequency between placebo and interven-
tion groups during the study period we used a correlated 
time-event model26 (GENMOD-procedure in SAS; Poisson 
distribution, compound symmetry correlation structure). To 
analyze the effects on health status, a longitudinal analysis 
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was performed on the CRQ-total score, while decline 
analyses for repeated FEV
1
 measurements were used for 
statistical testing of differences in annual lung function. The 
regression model for these outcomes accounted for correla-
tion between repeated measurements27 (PROC MIXED in 
SAS, compound symmetry correlation structure).
Results
The study population is described in Table 1. The number 
of responders differs from 25 (9%, ERS) to 44 (16%, ATS) 
depending on guideline used. Responders show a signifi-
cant higher proportion of females, almost equaling men, in 
comparison with nonresponders across all guidelines. Age, 
smoking behavior, pack-years, degree of obstruction, and 
reversibility to bronchodilator do not differ significantly.
The long-term effectiveness of fluticasone propionate 
relative to placebo in responders versus nonresponders is 
shown according to different guideline criteria. Outcome 
variables are exacerbation rate, health status, and postbron-
chodilator FEV
1
. On average, clinically relevant differences 
in health status were not reached. Responders according to 
ERS experienced a borderline significant effect of inhaled 
fluticasone on health status (0.29 points/year, P = 0.05), 
and to a lesser extent in BTS responders (0.26 points/year, 
P = 0.06). ATS-responders did not experience any significant 
benefit from long-term fluticasone use. Possible clinically 
relevant reductions in exacerbation rate (rate ratio 0.67) and 
FEV
1
 decline (39 mL/year) occurred in BTS responders, 
but did not reach statistical significance. These effects 
were similar (rate ratio 0.68, FEV
1
 decline 30 mL/year) in 
ERS-responders, while much smaller in ATS responders 
(rate ratio 0.78, FEV
1
 decline 8 mL/year).
Discussion
To our knowledge, this study for the first time prospectively 
relates the responses to long-term inhaled corticosteroid 
therapy to different cut-off points for prednisolone testing in 
primary care. Between 9% to 16% of the COPD population 
was classified as a responder depending on criteria used. 
On average, clinically relevant differences in health status 
were not reached. Responders according to the former ERS 
guideline (FEV
1
 increase of 10% predicted) experienced 
a borderline significant effect of inhaled fluticasone on 
health status (0.29 points/year, P = 0.05) during three years 
of treatment. A similar, but not significant effect on health 
status (0.26 points/year, P = 0.06) was seen using the for-
mer BTS criteria, while ATS responders showed less effect 
(0.20 points/year). Possible clinically relevant reductions 
in exacerbation rate (rate ratio 0.67) and FEV
1
 decline 
(39 mL/year) occurred in responders according to BTS, but 
did not reach statistical significance. Similar results were seen 
in the ERS group (rate ratio 0.68 and +30 mL, respectively) 
but were less similar when the ATS criteria was applied (rate 
ratio 0.77 and +8 mL, respectively).
Interestingly, the only other long-term prospective study21 
that assessed prednisolone testing on these outcomes, but 
not in a primary care population, concluded on the basis of 
using ATS criteria that there was ‘no relationship between the 
Table 1 Population characteristics of responders versus nonresponders according to former international guidelines13–15
Total group ERS ATS BTS
Responders Nonresponders Respodners Nonresponders Responders Nonresponders
number 286 25 261 44 242 35 251
(% of total) (9%) (91%) (16%) (84%) (12%) (88%)
Age (range) 59.1 (34–76) 59 59 59 59 59 59
gender (f/m) 77/209 12/13* 65/196 18/26* 59/183 16/19* 61/190
(% female) (27%) (48%) (25%) (41%) (24%) (46%) (24%)
smoking (curr/form) 125/161 9/16 116/145 14/30 111/131 11/24 114/137
(% current) (44%) (36%) (44%) (32%) (46%) (31%) (45%)
Pack years (sD) 28.2 (17.5) 29 28 29 28 31 28
FeV1 postBD (%pred) 69.4 (15.6) 69 69 68 70 65 70
FVC postBD (%pred) 89.9 (17.7) 94 89 91 90 91 90
FeV1/FVC (sD) 62.6 (11.8) 60 63 61 63 58 63
BD-Reversibility (%) 6.2 (5.1) 6 6 6 6 6 6
BMI (kg/m2) 26.3 (4.4) 26 26 25 27 25 27
Notes: *statistical difference between responders and nonresponders, P  0.05.
Abbreviations: ATs, American Thoracic society; BD, bronchodilators; BMI, body mass index; BTs, British Thoracic society; eRs, european Respiratory society; 
FeV1, forced expiratory volume in one second; FVC, forced vital capacity; sD, standard deviation.
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short term response to prednisolone and the rate of decline in 
FEV
1
 or health status’. In fact, our results are in line with that 
widely cited study, since we only found any possibly mean-
ingful results using the ERS and BTS criteria. In addition, the 
Isolde researchers looked at the so-called Callahan criteria 
(FEV
1
 increase of 20% of baseline), which were derived from 
a meta-analysis12 looking at oral corticosteroid therapy, not 
prednisolone testing. In fact, this cut-off indeed also showed a 
significant effect, but this was deemed by the Isolde research-
ers to be the result of confounding. Thus, the criteria used 
appears to matter and we cannot recommend the use of the 
former ATS criteria when performing prednisolone trials, 
based on our results and on those of the Isolde researchers.
In our study, the proportion of primary care COPD patients 
meaningfully labeled as responder ranges from 9% (ERS) 
to 12% (BTS), which is considerably lower than expected. 
We therefore fear that our study was underpowered, since 
estimates in literature ranged from 20%–30% responders. 
However, it is also possible that we underestimated the 
number of potential responders in the population, since 
for ethical reasons our study design provided a wash-out 
period to exclude all patients that experienced more than 
two exacerbations when inhaled steroids were taken in the 
three months preceding entry to the study.28 In our population, 
this means that steroid-dependent patients were not allowed 
to enter the study.
Contrary to the Isolde researchers, we found a significant 
gender difference in prednisolone responsiveness across 
all criteria groups. Women appear particularly prone to 
COPD when exposed to similar amounts of tobacco29 and 
interestingly, the proportion of female COPD patients 
responding to prednisolone was consistently higher than among 
nonresponders at baseline. No other significant differences 
were seen between responders and nonresponders in terms of 
age, lung function, current smoking, or pack-years of smok-
ing. This apparent gender difference in prednisolone response 
therefore deserves further study, since earlier studies probably 
did not include sufficient numbers of females with COPD, 
whose prevalence has been seen to rise only in recent years.
In this study, a clear history of asthma, allergic rhinitis or 
atopic eczema was an exclusion criterion, while reversibility 
to bronchodilators was not. However, we found no relation-
ship between prednisolone response and bronchodilator 
reversibility, which was very similar across all criteria groups 
(Table 1). We consider it highly relevant to clinical practice 
that reversibility to bronchodilators apparently does not 
correspond to prednisolone responsibility, since these terms 
are sometimes interchangingly used as parameters of the 
same phenomenon. These study data indeed suggest that the 
response to oral steroids may describe a different underlying 
inflammatory process than the response to bronchodilation, 
which is of a fundamentally different origin.
Our results suggest a borderline signif icant effect 
on health status in ERS responders, but is it clinically 
meaningful? The minimum clinical difference on the CRQ 
is 0.5 points, which is clearly higher than the 0.29 points 
reached on average in our study, which renders this result 
marginal. However, the rate ratio for exacerbations (32% less 
than placebo) and even the FEV
1
 decline (30 mL/year less 
than placebo) point in the same direction in both the ERS 
Table 2 Long-term effectiveness of fluticasone propionate versus placebo in responders and nonresponders on exacerbations, health 
status, and lung function according to different international guidelines13–15
Variables Total 
group
ERS ATS BTS
Responders Nonresponders Responders Nonresponders Responders Nonresponders
exacerbations 
(number/yr)
FLU
Pla
0.98
0.73
0.71
1.04
0.93
0.70
0.56
0.73
0.96
0.73
0.63
0.94
0.95
0.70
Rate ratio 1.30 0.68 1.33 0.77 1.32 0.67 1.36
health status 
(points/yr)
FLU
Pla
+0.15
+0.13
+0.30
+0.01
+0.14
+0.13
+0.29
+0.09
+0.14
+0.13
+0.29
+0.03
+0.14
+0.13
Annual difference 
(points)
+0.02 +0.29* +0.01 +0.20 +0.01 +0.26 +0.01
FeV1-change 
(mL/yr)
FLU
Pla
-59
-60
-67
-97
-58
-56
-61
-69
-59
-58
-60
-99
-59
-55
Annual difference 
(mL)
+1 +30 -2 +8 -1 +39 -4
Notes: *statistical difference between responders and nonresponders, P  0.05.
Abbreviations: ATs, American Thoracic society; BTs, British Thoracic society; eRs, european Respiratory society; FeV1, forced expiratory volume in one second; 
FLU, ; Pla, platelets.
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and BTS groups (33% less exacerbations and 39 mL/year 
less FEV
1
 decline, respectively), which may indicate pos-
sible clinical relevance. The systematical difference in 
effects on all three outcomes compared to the nonresponders 
(and indeed the total group of COPD patients) suggests that 
this rather small group of responders to prednisolone could 
be a limited subgroup in primary care, which would need 
different medical treatment. Since the number of responders 
(using the ERS or BTS criteria) now can be expected to 
be around 10% in a primary care population like ours, we 
think these results would probably need replication in a 
larger primary care study. This small but possibly relevant 
proportion is identical to the 10% that was found in the 
earlier meta-analysis on the benefits of oral corticosteroid 
therapy for COPD patients.12 As has been stated before,30 
it is important to keep an open mind about the possibility 
that there may be responder and nonresponder subgroups 
and to continue to seek ways to identify and characterize 
them, especially in primary care where heterogeneity is 
common.20
Conclusions
Oral steroid testing distinguishes a limited proportion of 
COPD patients, but does not reveal clinically relevant 
benefit from inhaled steroid treatment on health status. No 
significant effects on exacerbation rate and lung function 
decline occurred.
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